A re-analysis of a clinical trial of GlaxoSmithKline's antidepressant Seroxat suggests the drug is ineffective and unsafe in younger patients, contradicting its earlier conclusions. The new study ...
This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy ...
In October, the MHRA reviewed data from the earliest trials of Seroxat. The information was supplied by GlaxoSmithKline in the late Eighties, and it was the MHRA's responsibility to analyse the ...
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
On June 2, New York State Attorney General Eliot Spitzer sued GlaxoSmithKline (GSK) for repeated and persistent fraud, contending that the company failed to disclose information on the safety and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback